Victorian-2 Prevent: A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing The Impact of Inclisiran On Major Adverse Cardiovascular Events In Participants With Established Cardiovascular Disease

Grants and Contracts Details

StatusActive
Effective start/end date10/27/229/13/23

Funding

  • Novartis (domestic): $7,500.00